Cover Image
市場調查報告書

抗體、藥物複合體 (ADC)的全球市場:各藥物分析 (ADCETRIS, Kadcyla)、開發平台分析 (各相位、各作用機制、各連接試劑、各技術、各症狀)、未來展望

Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 297685
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
抗體、藥物複合體 (ADC)的全球市場:各藥物分析 (ADCETRIS, Kadcyla)、開發平台分析 (各相位、各作用機制、各連接試劑、各技術、各症狀)、未來展望 Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022
出版日期: 2017年02月13日 內容資訊: 英文 120 Pages
簡介

本報告提供全球抗體、藥物複合體(以下ADC)市場相關分析,整體產業結構,及已上市產品的市場趨勢,臨床實驗中的主要藥物的概要與今後的開發預測,近幾年的市場、企業趨勢,主要產業促進、阻礙因素,主要企業簡介等調查。

第1章 分析師的見解

第2章 分析方法

第3章 抗體、藥物複合體 (ADC):概要

第4章 ADC市場未來展望

  • ADCETRIS
    • 市場未來性
    • 市場規模與其預測(今後6年份)
  • Kadcyla

第5章 ADC的開發中產品分析

  • 各企業
    • 各臨床階段 (各相位)
    • 各藥物
    • 連接試劑的各類型
    • 各作用機制
    • 各技術
  • 各研究機關
    • 各相位
    • 各症狀
    • 各藥物
    • 連接試劑的各類型
    • 各作用機制

第6章 推動及阻礙市場要素

  • 推動因素
    • 全球各地的癌症患者的增加
    • 鏈接技術的進步:ADC市場重新運作
    • ADC市場促進的,對專利保護的努力
    • ADC的需求增加
  • 課題
    • 在生產方面的障礙與成本
    • 熟練的製造商不足
    • 在法規方面的課題

第7章 開發平台上的主要的ADC的未來性

  • 各企業
  • 各研究機關

第8章 市場趨勢和動靜

  • 在骨髓惡性腫瘤治療最前線的ADC
  • ADC對乳癌患者的效果

第9章 ADC產業的策略性的產業聯盟

第10章 企業分析

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. They combine the unique targeting property of monoclonal antibodies with the cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased tissues. Advancements in coupling monoclonal antibodies to cytotoxic drugs permit better control of drug pharmacokinetics, and significantly improve delivery to target tissue. Potent novel anti-cancer drugs can now be used to target cancers, while minimizing the exposure of healthy tissue. The recent approvals of two potent ADCs - ADCETRIS and Kadcyla, followed by several Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in this industry.

According to the RNCOS report entitled "Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022", the ADC market is poised to reach US$ 18.1 Billion by 2022. In this report, there is in-depth market analysis of ADCETRIS and Kadcyla. The market potential of these ADCs is estimated considering that these are being tested in clinical trials for several cancer indications, besides the ones which have already been approved. The depicted ADCs are expected to show their complete market potential soon in the coming years.

Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, mode of action, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry's growth.

In the end, the report enlists some of the key players in the ADC market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2022

  • 4.1 ADCETRIS
    • 4.1.1 Market Potential
    • 4.1.2 Market Size and Forecast to 2022
  • 4.2 Kadcyla
    • 4.2.1 Market Potential
    • 4.2.2 Market Size and Forecast to 2022

5. ADC Pipeline Analysis

  • 5.1 By Companies
    • 5.1.1 By Clinical Phase
    • 5.1.2 By Indication
    • 5.1.3 By Drug
    • 5.1.4 By Type of Linker
    • 5.1.5 By Mode of Action
    • 5.1.6 By Technology
  • 5.2 By Research Organizations
    • 5.2.1 By Phase
    • 5.2.2 By Indication
    • 5.2.3 By Drug
    • 5.2.4 By Type of Linker
    • 5.2.5 By Mode of Action

6. Drivers and Challenges

  • 6.1 Drivers
    • 6.1.1 Rising Global Cancer Epidemics
    • 6.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
    • 6.1.3 Efforts towards Patent Protection to Drive ADC Market
    • 6.1.4 Increasing Demand for Antibody Drug Conjugates
  • 6.2 Challenges
    • 6.2.1 Production Hurdles and Cost
    • 6.2.2 Inadequacy of Experienced Manufacturers
    • 6.2.3 Regulatory Challenges

7. Major Potential ADCs in Pipeline

  • 7.1 By Companies
    • 7.1.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
    • 7.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
    • 7.1.3 Indatuximab Ravtansine/BT-062 - Biotest
    • 7.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
    • 7.1.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
    • 7.1.6 DMUC-4064A/RG7882 - Roche Genentech
    • 7.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
    • 7.1.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
  • 7.2 By Research
    • 7.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
    • 7.2.2 Panitumumab-IRDye800 - Eben Rosenthal/Stanford University
    • 7.2.3 90Yttrium Ibritumomab Tiuxetan (Zevalin) - Biogen Idec in Collaboration with Soroka University Medical Center
    • 7.2.4 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital

8. Trends and Developments

  • 8.1 ADC at the Forefront of Treating Hematological Malignancies
  • 8.2 ADCs Proving Advantageous for Breast Cancer Patients

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment

  • 10.1 Seattle Genetics, Inc.
  • 10.2 F. Hoffman-La Roche Ltd.
  • 10.3 ImmunoGen, Inc.
  • 10.4 Bayer AG
  • 10.5 Novartis AG
  • 10.6 Takeda Pharmaceutical Company Limited
  • 10.7 Immunomedics, Inc.
  • 10.8 Agensys, Inc.
  • 10.9 Concortis Biotherapeutics
  • 10.10 NBE-Therapeutics

List of Figures:

  • Figure 3-1: ADC - Mechanism of Action
  • Figure 4-1: Global - ADC Market (Billion US$), 2015-2022
  • Figure 4-2: Global - ADCETRIS Market (Billion US$), 2015-2022
  • Figure 4-3: Global - Kadcyla Market (Billion US$), 2015-2022
  • Figure 5-1: Global - ADCs Pipeline by Developing Organizations (%), 2016
  • Figure 5-2: Global - ADC Pipeline of Companies by Clinical Phase (%), 2016
  • Figure 5-3: Global - ADC Pipeline of Companies by Indication (%), 2016
  • Figure 5-4: Global - ADC Pipeline of Companies by Drug (%), 2016
  • Figure 5-5: Global - ADC Pipeline of Companies by Type of Linker (%), 2016
  • Figure 5-6: Global - ADC Pipeline of Companies by Mode of Action (%), 2016
  • Figure 5-7: Global - ADC Pipeline of Companies by Technology (%), 2016
  • Figure 5-8: Global - ADC Pipeline of Research Organization by Clinical Phase (%), 2016
  • Figure 5-9: Global - ADC Pipeline of Research Organization by Indication (%), 2016
  • Figure 5-10: Global - ADC Pipeline of Research Organization by Drug (%), 2016
  • Figure 5-11: Global - ADC Pipeline of Research Organization by Type of Linker (%), 2016
  • Figure 5-12: Global - ADC Pipeline of Research Organization by Mode of Action (%), 2016
  • Figure 10-1: Novartis AG - Net Sales Breakup by Business Segments (%), 2016
  • Figure 10-2: Novartis AG - Net Sales Breakup by Geography (%), 2016
  • Figure 10-3: Takeda Pharmaceutical Company Limited - Ethical Drugs Revenue Breakup by Geography (%), 2016
  • Figure 10-4: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2016
  • Figure 10-5: Astellas Pharma Inc. - Sales Breakup by Business Segments (%), 2016
  • Figure 10-6: Astellas Pharma Inc. - Sales Breakup by Geography (%), 2016

List of Tables:

  • Table 4-1: Potential Patients for ADCETRIS (2012)
  • Table 4-2: Ongoing Trials for ADCETRIS
  • Table 4-3: Potential Patients for Kadcyla (2012)
  • Table 4-4: Ongoing Trials for Kadcyla
  • Table 5-1: Global - ADC Pipeline of Companies
  • Table 5-2: Global - ADC Pipeline of Research Organization
  • Table 9-1: Strategic Collaborations in the ADC Industry (2014-2016)
  • Table 10-1: Top Companies by ADCs in Pipeline (2016)
  • Table 10-2: Seattle Genetics, Inc. - ADCs in Pipeline
  • Table 10-3: Seattle Genetics, Inc. - Key Financials (Million US$), 2013-2015
  • Table 10-4: Seattle Genetics, Inc. - Strengths and Weaknesses
  • Table 10-5: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
  • Table 10-6: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2013-2015
  • Table 10-7: F. Hoffman-La Roche Ltd. - Strengths and Weaknesses
  • Table 10-8: ImmunoGen, Inc. - ADCs in Pipeline
  • Table 10-9: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
  • Table 10-10: ImmunoGen, Inc. - Strengths and Weaknesses
  • Table 10-11: Bayer AG - ADCs in Pipeline
  • Table 10-12: Bayer AG - Key Financials (Million US$), 2013-2015
  • Table 10-13: Bayer AG - Strengths and Weaknesses
  • Table 10-14: Novartis AG - ADCs in Pipeline
  • Table 10-15: Novartis AG - Key Financials (Million US$), 2014-2016
  • Table 10-16: Novartis International AG - Strengths and Weaknesses
  • Table 10-17: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
  • Table 10-18: Millenium Pharmaceuticals - ADCs in Pipeline
  • Table 10-19: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
  • Table 10-20: Immunomedics, Inc. - ADCs in Pipeline
  • Table 10-21: Immunomedics, Inc. - Key Financials (Million US$), 2014-2016
  • Table 10-22: Agensys, Inc. - ADCs in Pipeline
  • Table 10-23: Astellas Pharma Inc. - Key Financials (Million US$), 2014-2016
  • Table 10-24: Oxford BioTherapeutics - ADCs in Pipeline
  • Table 10-25: Concortis Biotherapeutics - ADCs in Pipeline
  • Table 10-26: NBE-Therapeutics - ADCs in Pipeline
Back to Top